NEW YORK, Jan. 22, 2016 -- Gainey McKenna & Egleston announces that an action has been filed in the United States District Court for the Southern District of California against the directors and/or officers of BofI Holding, Inc. (“BofI” or the “Company”) (NASDAQ:BOFI). The action alleges that the officers and directors of BofI breached their fiduciary duties of loyalty, good faith and candor that resulted in substantial harm to the Company.
The Complaint further alleges that Defendants each breached their duties of loyalty and good faith by causing the Company to make false and/or misleading statements and/or failing to disclose that: (a) the Company was doing business with foreign nationals who should have been off-limits under federal anti-money-laundering laws; (b) the Company had as many as 200 customer accounts without tax identification numbers, contrary to BofI’s representations to the Office of the Comptroller of the Currency (“OCC”), its primary regulator; (c) as a result, the Company’s revenue and financial results were overstated; (d) the Company’s financial statements were not prepared in accordance with the Generally Accepted Accounting Principles (“GAAP”); (e) the Company lacked adequate internal and financial controls; and (f) as a result of the foregoing, the Company’s financial statements were materially false or misleading at all relevant times.
If you are an investor in BofI securities and wish to discuss your rights, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



